Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?
Ji‐Jin Yao(Sun Yat-sen University), Yingming Sun(Sun Yat-sen University), Wangjian Zhang(Sun Yat-sen University), Qiaodan Liu(Sun Yat-sen University), Wayne R. Lawrence(Albany State University), Zhigang Liu, Jun Ma(Shanghai Institute of Technology), Siyang Wang(South China University of Technology), Fan Zhang(Sichuan University), Li Lin(Sun Yat-sen University), Ya‐Nan Jin(Xi'an Medical University), Huaili Zhou(Sun Yat-sen University), Guan‐Qun Zhou(Sun Yat-sen University)
Cited by 11
Related Papers
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy
|PLoS ONE|2012|703
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483